Navigation Links
Hospira Reports Fourth-Quarter and Full-Year 2012 Results
Date:2/13/2013

be in a range of $2.05 to $2.20, representing growth of 2 to 9 percent.

The reconciliation between the projected 2013 adjusted* diluted earnings per share and projected GAAP diluted earnings per share follows:

Diluted earnings per share -- adjusted*$2.05 - $2.20Estimated amortization of intangible assets related to certain acquisitions (mid-point of an estimated range of $0.29 to $0.33 per diluted share)$(0.31)Estimated charges for certain quality and product-related matters (mid-point of an estimated range of $0.15 to $0.23 per diluted share)$(0.19)Estimated charges related to capacity expansion (mid-point of an estimated range of $0.15 to $0.19 per diluted share)$(0.17)Estimated acquisition and integration-related charges associated with the pending acquisition of an API-related business from Orchid Chemicals & Pharmaceuticals (mid-point of an estimated range of $0.04 to $0.06 per diluted share)$(0.05)Estimated charges related to facilities optimization (mid-point of an estimated range of $0.00 to $0.02 per diluted share)$(0.01)Diluted earnings per share -- GAAP$1.32 - $1.47The adjusting items are shown net of tax in aggregate of $57 million, which is calculated for the specified adjustments stated above, based on the statutory tax rates in the various tax jurisdictions in which the items are expected to occur.

The company projects that cash flow from operations in 2013 will range between $350 million and $400 million. Depreciation and amortization is expected to be $255 million to $275 million. Capital expenditures are projected to range between $425 million and $475 million.

*Use of Non-GAAP Financial MeasuresAdjusted measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Hospira to Present at Upcoming Investor Conferences
2. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
3. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
4. Hospira Reports Third-Quarter 2012 Results
5. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
6. Hospira Reports Second-Quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira to Host Conference Call for Second-quarter 2012 Results
9. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
10. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), ... from two pre-clinical studies that,provide evidence ... combining nab-paclitaxel (ABRAXANE(R) for Injectable,Suspension (paclitaxel ... VEGF inhibitor drugs like,bevacizumab (Avastin(R)) at ...
... WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. ... first-time data from a pre-clinical study,evaluating ... nab-rapamycin,(ABI-009), an albumin-bound mTOR kinase inhibitor, ... Research (AACR) Annual Meeting held,April 14-18, ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... 2 copies of variant, puffing before age 17 boosted odds ... -- People with certain common genetic variations that affect their ... life-long nicotine addicts if they begin smoking before they turn ... people who begin smoking at a young age are more ...
... NEW YORK, July 17 Fresh Harvest Products,Inc. ... is expanding and,enhancing its long standing commitment to ... offerings, through a new initiative to,build natural and ... side the Fresh Harvest brands,through our network., ...
... A NEW SOUTH AFRICA TO PRODUCE, HACHETTE AUDIO TO ... PROGRAMS SERVING AFRICAN AIDS ORPHANS, LOS ANGELES, July ... week, Artists for a New South Africa (ANSA) announced ... African,Folktales, an award-winning book of legendary tales hand-picked by ...
... Uninsured Fail to Address the High Percentage of people with Mental ... ... July 17, 2008 -- New data indicates that more than one ... or addiction disorder, or both., , , , ,Many state healthcare ...
... France, July 17 - First-Half 2008 Revenue ... Constant Exchange Rates Essilor International, the ... EUR1,520.3 million for the six months,ended June 30, 2008, ... Like-for-like growth was 5.4%, in line with trend rates, ...
... a privately held medical device manufacturer focusing on ... today announced that the company has closed a ... leading venture capital firms active in medical technology. ... Foundation Medical Partners and were joined in the ...
Cached Medicine News:Health News:Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 2Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 3Health News:Uninsured With Mental Illness and Addiction Disorders Not Covered by State Healthcare Initiatives 2Health News:Essilor - First-Half 2008 Revenue 2Health News:Essilor - First-Half 2008 Revenue 3Health News:Essilor - First-Half 2008 Revenue 4Health News:Essilor - First-Half 2008 Revenue 5Health News:Vertos Medical Inc. Completes Series C Financing 2Health News:Vertos Medical Inc. Completes Series C Financing 3Health News:Vertos Medical Inc. Completes Series C Financing 4
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
... Millex Filter Units,Filter units with ... hydrophobic Fluoropore membrane are ideal for ... venting of sterile containers, and for ... sterile 25 mm Millex filter units ...
... Undercounter refrigerator -4C. ... is reversible. Interior light. ... Two see-through drawers. Two ... large bottles. Adjustable thermostat. ...
Designed to meet the requirements of reagent grade water for routine analysis....
Medicine Products: